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Objective—To characterise the surgical feasibility and outcomes of robot-assisted radical
cystectomy (RARC) for pathological T4 bladder cancer.
Patients and Methods—Retrospective evaluation of a prospectively maintained International
Radical Cystectomy Consortium database was conducted for 1118 patients who underwent RARC
between 2003 and 2012.
We dichotomised patients based on pathological stage (≤pT3 vs pT4) and evaluated demographic,
operative and pathological variables in relation to morbidity and mortality.
Results—In all, 1000 ≤pT3 and 118 pT4 patients were evaluated. The pT4 patients were older
than the ≤pT3 patients (P = 0.001).
The median operating time and blood loss were 386 min and 350 mL vs 396 min and 350 mL for
p T4 and ≤pT3, respectively.
The complication rate was similar (54% vs 58%; P = 0.64) among ≤pT3 and pT4 patients,
respectively. The overall 30-and 90-day mortality rate was 0.4% and 1.8% vs 4.2% and 8.5% for
≤pT3 vs pT4 patients (P < 0.001), respectively.
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The body mass index (BMI), American Society of Anesthesiology score, length of hospital stay
(LOS) >10 days, and 90-day readmission were significantly associated with complications in pT4
patients.
Meanwhile, BMI, LOS >10 days, grade 3–5 complications, 90-day readmission, smoking,
previous abdominal surgery and neoadjuvant chemotherapy were significantly associated with
mortality in pT4 patients. On multivariate analysis, BMI was an independent predictor of
complications in pT4 patients, but not for mortality.
Conclusions—RARC for pT4 bladder cancer is surgically feasible but entails significant
morbidity and mortality.
BMI was independent predictor of complications in pT4 patients.
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Introduction
Although radical cystectomy (RC) and pelvic lymph node (LN) dissection is well
established as the ‘gold-standard’ treatment for muscle-invasive and high-risk non-muscleinvasive bladder cancer [1], the management of locally advanced bladder cancer continues
to be controversial. In the absence of local treatment, locally advanced bladder cancer can
lead to adverse pelvic and urinary symptomology, in addition to disease progression, and
such local symptoms significantly decreases patient quality of life [2]. Accordingly, it has
been suggested that patients with locally advanced bladder cancer may benefit from RC as a
palliative procedure or as part of a multimodality attempt towards curative intent [3,4].
However, due to significant reported morbidity and mortality of open RC in the setting of
locally advanced bladder cancer, local extirpation has been questioned [5].
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Robot-assisted RC (RARC) has emerged as an alternative approach to open RC based on an
improved profile in terms of blood loss, transfusion rate, need for postoperative analgesia,
recovery of bowel function, and length of hospital stay (LOS) [6–8]. Prior to the present
study, the application of a robot-assisted approach to locally advanced bladder cancer has
not been appropriately assessed due to previous selection bias for low-volume and LNnegative disease. It has been questioned whether the robot-assisted approach may lead to
inferior outcomes in this setting due to a lack of tactile sensation, which may aid in avoiding
positive surgical margins and in achieving complete resection. We sought to characterise the
feasibility and surgical outcomes of RARC for pathological T4 bladder cancer.

Patients and Methods
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A retrospective analysis of the prospectively maintained database of the International
Robotic Cystectomy Consortium (IRCC), a collaborative effort of over 20 institutions
comprising ≈1300 patients treated with RARC for bladder cancer, was performed. We
dichotomised patients based on pathological tumour stage into patients with ≤pT3 and pT4
tumours.
Specific clinical and pathological data was collected and analysed for patients which
included: demographic variables (age, gender, body mass index [BMI], American Society of
Anesthesiology [ASA] score, and smoking), preoperative disease characteristics
(preoperative chemotherapy, abdominal surgery, and radiation), operative variables
(estimated blood loss [EBL], LOS, length of intensive care unit (ICU) stay, type of
diversion, and technique of diversion; intracorporeal vs extracorporeal), pathological
characteristics (tumour stage, LN yield, and number of positive LNs), and 90-day
postoperative outcomes (complications, readmission and mortality).
Patient comorbidity was assessed preoperatively using the ASA score. Complications were
identified, defined and classified using the modified Clavien system [9]. The technique of
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RARC and pelvic LN dissection varied according to the individual surgeon and institution.
Urinary diversion was performed both by intracorporeal and extracorporeal techniques.
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Descriptive statistics, such as frequencies and relative frequencies, were computed for all
categorical outcomes. Numeric outcomes were summarised using summary statistics such as
the mean, standard deviation (SD), range, etc. Associations between baseline characteristics
and pathological stage were statistically assessed using Fisher's exact test for categorical
outcomes, and Wilcoxon rank-sum test for continuous outcomes. Univariate and
multivariate logistic regression models were fit to evaluate preoperative, operative and
postoperative predictors of readmission, complication and mortality. All statistical analysis
was performed using SAS software (version 9.3, SAS Institute Inc., Cary, NC, USA). All
tests were two-side, with statistical significance defined as P < 0.05.

Results
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In all, 1000 ≤pT3 and 118 pT4 patients were analysed. The pT4 patients were older than the
≤pT3 patients, at a mean of 70 and 67 years, respectively (P = 0.001). Both groups were
comparable for gender, ASA score, rates of prior abdominal surgery or neoadjuvant
chemotherapy, LOS, EBL and operating time. The intraoperative blood transfusion rate was
significantly higher among pT4 patients compared with ≤pT3 patients, at 12% vs 4%,
respectively (P = 0.049).
There were statistically significant differences between ≤pT3 and pT4 patients for BMI
(27.8 and 26.3 kg/m2, respectively; P = 0.008), and salvage cystectomy after radiation (1.4%
and 5.9%, respectively; P < 0.001).
The mean number of LNs removed was not significantly different between ≤pT3 and pT4
patients (19.2 vs 17.3, respectively; P = 0.145); however, more pT4 patients had positive
LNs (55% vs 23%; P < 0.001). The rate of positive surgical margin at cystectomy was 4%
and 31.5% (P = 0.001) for ≤pT3 and pT4 patient, respectively.
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The mean follow-up time for pT4 and ≤pT3 patients was 10.6 and 17 months, respectively
(P < 0.001). The pT4 patients underwent ileal conduit more often than the ≤pT3 patients
(87% vs 66%; P < 0.001). The length of ICU stay was 1 day and 1.8 days for ≤pT3 and pT4
patient, respectively (P < 0.001). The complication rate was similar between ≤pT3 and pT4
patients (54% vs 58%) with 19.0% and 20% of the complications being Clavien grade ≥3,
respectively. The 90-day readmission was similar. The overall 30- and 90-day mortality rate
was 0.4% and 1.8% vs 4.2% and 8.5% for ≤pT3 and pT4 patients, respectively (P < 0.001;
Table 1).
On univariate analysis, BMI, ASA score, LOS >10 days, and 90-day readmission were
significantly associated with complications in pT4 patients (Table 2). However, on
multivariate analysis, only BMI was an independent predictor of complications in pT4
patients (Table 2). Meanwhile, on univariate analysis BMI, LOS >10 days, Clavien grade 3–
5 complications, 90-day readmission, smoking, previous abdominal surgery, ileal conduit
diversion and neoadjuvant chemotherapy were significantly associated with overall
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mortality in pT4 patients. On multivariate analysis, BMI was an independent predictor of
complications in pT4 patients, but not an independent predictor for mortality (Tables 2,3).
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Discussion
To date, only small case series have been reported regarding RC in pT4 bladder cancer, and
data about cancer outcomes are sparse, and no reports specifically address efficiency of
RARC in locally advanced bladder cancer [10,11].
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Long-term survival is dismal when bladder cancer invades the pelvic sidewall or adjacent
structures, yet RC can provide palliation and accurate staging [12]. The rationale behind
advocating RC in locally advanced disease could be explained by increasing evidence
supporting meticulous surgical clearance with extended lymphadenectomy both of which
can significantly impact disease-free survival [13]. Hence, ‘debulking’ surgery may have
oncological benefit in bladder cancer, as is well established in other malignancies, e.g.
ovarian cancer. In the randomised Southwest Oncology Group (SWOG) trial in which
neoadjuvant chemotherapy followed by RC compared with RC alone showed a survival
benefits in patients who received neoadjuvant chemotherapy with T2 disease (105 vs 75
months; P = 0.05) and for T3 or T4a disease (65 vs 24 months; P = 0.05) [3]. The data for
adjuvant chemotherapy are less compelling. However, benefits may be derived for patients
who progress to extensive disease [14,15]. Neoadjuvant chemotherapy was administered to
14.4% patients in present cohort, despite proved efficacy.
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The present outcomes show that operating time, EBL and LOS were comparable between
pT4 and ≤pT3 patients. These findings support similar observations by Hayn et al. [16] who
reported an EBL of 400 mL, operating time of 6.3 h and LOS of 8 days. The present overall
90-day complication rate was not higher among pT4 patients; however, 90-day mortality
was. The present complication rates were similar to those in previously published RARC
series, although the high-grade complications were higher [7,8]. Pruthi et al. [17] reported
major surgical complications (Clavien grade ≥3) in 8% of their patients, with 13% of
patients having non-organ-confined disease. Higher mortality and high-grade complications
in the present series could be explained by the advanced nature of the disease in our series,
which has not been addressed in RARC literature and the multi-institutional nature of our
series, which represent variation in operative expertise, patient selection, and quality of
perioperative care. In the present study, there was no difference in 90-day readmission
between ≤pT3 and pT4 patients. Stimson et al. [18] reported a 90-day readmission rate of
26.6%, which was slightly higher than our present pT4 patients (19.5%) for the same period.
In a study by Nagele et al. [10], 20 patients underwent RC for locally advanced bladder
cancer (T4a/b), the LOS was 19 days, 50% of patients received an intraoperative blood
transfusion and 50% died within a mean (range) interval of 7 (2–19) months. Furthermore,
Hemal et al. [11] evaluated the feasibility of laparoscopic RC for loco-regionally advanced
bladder cancer in 13 patients and reported a 57% blood transfusion rate, LOS was 11 days,
and there was one mortality at ≤30 days.
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In all, 45% of patients with pT4 disease in the present study underwent a LN dissection with
negative LNs and a mean LN yield of 17, similar to Tilki et al. [19] who reported 54%
incidence of LN metastasis in pT4 bladder cancer. The impact of LN metastasis on survival
after RC was reported by Shariat et al. [20] who found that in patients with non-organconfined and LN-negative disease the progression-free survival (PFS) and cancer-specific
survival (CSS) were 55% and 59%, respectively, compared with patients with LN
metastasis, where PFS and CSS were only 29% and 37%, respectively.
Local cancer control in terms of total resection is an important predictor of survival in
patients with pT4, as patients with positive margins are significantly more likely to have
disease recurrence, as demonstrated by Dotan et al. [21]. In the present study, 31.5% of pT4
patients had positive margins compared with 24% reported in an open RC series by Novara
et al. [22] and 25% by Tilki et al. [19]. Due to limitation of data, sites of positive margins
could not be defined.
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One of the primary aims of the present study was to identify predictors of complications and
mortality in pT4 patients after RARC. BMI was the only independent predictor of
complications. Reyes et al. [23] reported a higher incidence of infection-related
complications in patients with higher BMI. Kouba et al. [24] found more stomal
complications after RC and ileal conduit diversion in obese patients. In contrast, Poch et al.
[25] found that RARC and intracorporeal ileal conduit was feasible for overweight and
obese patients compared with patients with normal BMI, and other investigators have found
no association between BMI and complications after RC, including RARC [26].
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The present study has its limitations. First, the limitations inherent to retrospective analysis.
Given the large number of surgeons and their variability, selection and reporting bias might
have influenced the results. Second, most surgeons in the IRCC had previous experience in
robot-assisted surgery. Thus, results might not be applicable to all urological surgeons.
Third, the number of patients varied widely among the institutions. Thus, the overall
outcomes might have been influenced by data from the institutions with greater experience.
It is crucial to consider the economic impact of robot use to fully evaluate this approach;
however, the present data are lacking regarding the cost. Finally, we did not have
prospective data on outcomes for functional status and quality of life outcomes. Additional
follow-up is needed to assess any long-term oncological or survival outcomes.
In conclusion, RARC for locally advanced bladder cancer is surgically feasible with
significant morbidity and mortality. BMI was found to be an independent predictor of
complications in pT4 patients.

Abbreviations
ASA

American Society of Anesthesiology score

CSS

cancer-specific survival

EBL

estimated blood loss

ICU

intensive care unit
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IRCC

International Radical Cystectomy Consortium

LN

lymph node

LOS

length of hospital stay

PFS

progression-free survival

(RA)RC

(robot-assisted) radical cystectomy

References

NIH-PA Author Manuscript
NIH-PA Author Manuscript

1. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder
cancer: update of the EAU guidelines. Eur Urol. 2011; 59:1009–18. [PubMed: 21454009]
2. Lodde M, Palermo S, Comploj E, et al. Four years experience in bladder preserving management for
muscle invasive bladder cancer. Eur Urol. 2005; 47:773–9. [PubMed: 15925072]
3. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared
with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349:859–66.
[PubMed: 12944571]
4. Power NE, Kassouf W, Bell D, et al. Natural history of pT3-4 or node positive bladder cancer
treated with radical cystectomy and neoadjuvant chemotherapy in a contemporary North-American
multi-institutional cohort. Can Urol Assoc J. 2012; 6:E217–23. [PubMed: 23283097]
5. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder
cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19:666–75. [PubMed: 11157016]
6. Wang GJ, Barocas DA, Raman JD, Scherr DS. Robotic vs open radical cystectomy: prospective
comparison of perioperative outcomes and pathological measures of early oncological effcacy. BJU
Int. 2008; 101:89–93. [PubMed: 17888044]
7. Nix J, Smith A, Kurpad R, Nielsen ME, Wallen EM, Pruthi RS. Prospective randomized controlled
trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic
results. Eur Urol. 2010; 57:196–201. [PubMed: 19853987]
8. Guru KA, Wilding GE, Piacente P, et al. Robot-assisted radical cystectomy versus open radical
cystectomy: assessment of postoperative pain. Can J Urol. 2007; 14:3753–6. [PubMed: 18163928]
9. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with
evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240:205–13.
[PubMed: 15273542]
10. Nagele U, Anastasiadis AG, Merseburger AS, et al. The rationale for radical cystectomy as
primary therapy for T4 bladder cancer. World J Urol. 2007; 25:401–5. [PubMed: 17525849]
11. Hemal AK, Kolla SB, Wadhwa P. Evaluation of laparoscopic radical cystectomy for locoregionally advanced bladder cancer. World J Urol. 2008; 26:161–6. [PubMed: 18030474]
12. Stewart BH, Novick AC. Current perspectives on palliative therapy in cancer of the bladder.
Cancer Res. 1977; 37:2781–8. [PubMed: 68815]
13. Konety BR, Joslyn SA, O'Donnell MA. Extent of pelvic lymphadenectomy and its impact on
outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance,
Epidemiology and End Results Program data base. J Urol. 2003; 169:946–50. [PubMed:
12576819]
14. Studer UE, Bacchi M, Biedermann C, et al. Adjuvant cisplatin chemotherapy following cystectomy
for bladder cancer: results of a prospective randomized trial. J Urol. 1994; 152:81–4. [PubMed:
8201695]
15. Lehmann J, Franzaring L, Thuroff J, Wellek S, Stockle M. Complete long-term survival data from
a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder
cancer. BJU Int. 2006; 97:42–7. [PubMed: 16336326]
16. Hayn MH, Hellenthal NJ, Hussain A, Stegemann AP, Guru KA. Defining morbidity of robotassisted radical cystectomy using a standardized reporting methodology. Eur Urol. 2011; 59:213–
8. [PubMed: 21109343]
BJU Int. Author manuscript; available in PMC 2014 October 14.

Al-Daghmin et al.

Page 8

NIH-PA Author Manuscript
NIH-PA Author Manuscript

17. Pruthi RS, Nielsen ME, Nix J, Smith A, Schultz H, Wallen EM. Robotic radical cystectomy for
bladder cancer: surgical and pathological outcomes in 100 consecutive cases. J Urol. 2010;
183:510–4. [PubMed: 20006884]
18. Stimson CJ, Chang SS, Barocas DA, et al. Early and late perioperative outcomes following radical
cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol. 2010;
184:1296–300. [PubMed: 20723939]
19. Tilki D, Svatek RS, Karakiewicz PI, et al. Characteristics and outcomes of patients with pT4
urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J
Urol. 2010; 183:87–93. [PubMed: 19942232]
20. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional
cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research
Consortium. J Urol. 2006; 176:2414–22. [PubMed: 17085118]
21. Dotan ZA, Kavanagh K, Yossepowitch O, et al. Positive surgical margins in soft tissue following
radical cystectomy for bladder cancer and cancer specific survival. J Urol. 2007; 178:2308–13.
[PubMed: 17936804]
22. Novara G, Svatek RS, Karakiewicz PI, et al. Soft tissue surgical margin status is a powerful
predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J
Urol. 2010; 183:2165–70. [PubMed: 20399473]
23. Reyes MA, Nieder AM, Kava BR, Soloway MS, Manoharan M. Does body mass index affect
outcome after reconstruction of orthotopic neobladder? Urology. 2007; 69:475–8. [PubMed:
17382148]
24. Kouba E, Sands M, Lentz A, Wallen E, Pruthi RS. Incidence and risk factors of stomal
complications in patients undergoing cystectomy with ileal conduit urinary diversion for bladder
cancer. J Urol. 2007; 178:950–4. [PubMed: 17632147]
25. Poch MA, Stegemann A, Chandrasekhar R, Hayn M, Wilding G, Guru KA. Does body mass index
impact the performance of robot-assisted intracorporeal ileal conduit? J Endourol. 2012; 26:857–
60. [PubMed: 22332715]
26. Kauffman EC, Ng CK, Lee MM, Otto BJ, Wang GJ, Scherr DS. Early oncological outcomes for
bladder urothelial carcinoma patients treated with robotic-assisted radical cystectomy. BJU Int.
2011; 107:628–35. [PubMed: 20883479]

NIH-PA Author Manuscript
BJU Int. Author manuscript; available in PMC 2014 October 14.

Al-Daghmin et al.

Page 9

Table 1
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Patient demographics.
P

Pathological stage ≤3

Pathological stage 4

1000

118

mean (SD)

67 (0.4)

70 (0.9)

median (range)

68.0 (26-90)

72.0 (28-90)

80

76

0.40

mean (SD)

27.8 (0.2)

26.3 (0.5)

0.01

Obese (>30 kg/m2), n (%)

78 (9)

9 (8)

0.90

Preoperative characteristics
Overall number of patients
Age, years

0.001

Male gender, %
BMI,

kg/m2:

ASA score ≥3, n (%)

578 (58)

77 (66)

0.12

Neoadjuvant chemotherapy, n (%)

139 (14)

17(14)

0.90

673 (93)

63 (76)

Clinical stage, n (%)

<0.001

≤T2
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52 (7)

20 (24)

Preoperative radiation, n (%)

>T2

14 (1.4)

7 (5.9)

Prior abdominal surgery, n (%)

421 (42)

46 (39)

Diversion type, n (%):

<0.001
0.52
<0.001

ileal conduit

659 (66)

103 (87)

continent

341 (34)

15 (13)

intracorporeal

755 (76)

94 (80)

extracorporeal

208 (21)

22 (19)

Positive surgical margins, n (%)

43 (4.4)

34(31.5)

<0.001

LN positive, n (%)

228 (23)

65 (55)

<0.001

mean (SD)

19.2 (0.4)

17.3 (1.1)

median (range)

18 (0.0-74.0)

17 (0.0-54.0)

Diversion location, n (%):

0.625

Pathological outcomes

LN yield:

0.15
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Follow-up, months:

<0.001

mean (SD)

17.0 (0.6)

10.6 (1.2)

median (range)

11 (0.0-85.0)

6 (0.0-61)

Perioperative outcomes
Overall operating time, min

0.47

mean (SD)

406.0 (3.9)

394.6 (9.6)

median (range)

396 (50.0-862)

386 (0.0-618)

450.9 (12.1)

522.8 (51.5)

350.0 (0.0-3900)

350.0 (0.0-3700)

10 (4.0)

4 (11.8)

EBL, mL:

0.47

mean (SD)
median (IQR)
Intraoperative transfusion, n (%)

0.049
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Pathological stage ≤3

Pathological stage 4

mean (SD)

1.0 (0.1)

1.8 (0.4)

median (IQR)

0.0 (0-36)

1.0 (0-21)

ICU stay, days:

P
<0.001
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Hospital stay, days:

0.84

mean (SD)

11.1 (0.3)

11.1 (0.7)

median (IQR)

9.0 (0-78)

9.0 (1-57)

Clavien 1-2

349 (35)

45 (38)

Clavien 3-5

190 (19)

24 (20)

Complications, n (%)

0.64

Readmission, n (%)

0.32

30 days

114 (11)

9 (8)

90 days

174 (17.4)

23 (19.5)

30 days

4 (0.4)

5 (4.2)

90 days

18 (1.8)

10 (8.5)

Mortality, n (%)

<0.001
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Table 2
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Univariable and multivariate logistic regression analysis to evaluate variables associated with 90-day
complications.
Variable

90-Day complications
OR (95% CI)

P

Gender (female vs male)

1.0 (0.43-2.34)

1.000

Age at surgery (10-year interval)

1.1 (0.72-1.58)

0.744

Preoperative variables - univariable analysis

(kg/m2)

1.1 (1.04-1.22)

0.005

Obese (BMI >30 kg/m2, yes/no)

8.0 (0.97-66.34)

0.054

BMI

Preoperative chemotherapy (yes/no)

1.2 (0.41-3.22)

0.79

Current smoker (yes/no)

2.42 (0.98-5.98)

0.06

ASA 3-4 vs 1-2

0.50 (0.23-1.09)

0.08

Preoperative variables - multivariable analysis

NIH-PA Author Manuscript

Gender (male vs female)

1.30 (0.43-3.92)

0.65

Age at surgery (10-year interval)

1.20 (0.72-1.99)

0.49

BMI (kg/m2)

1.12 (1.02-1.22)

0.02

Current smoker (yes/no)

2.90 (0.98-8.68)

0.06

ASA (1-2 vs 3-4)

0.34 (0.12-1.02)

0.05

Preoperative chemotherapy (yes/no)

0.90 (0.25-3.10)

0.85

Operating room time (≤6vs >6 h)

0.58 (0.27-1.25)

0.16

EBL (≤800 vs >800 mL)

3.0 (0.90-10.10)

0.08

Intraoperative variables - univariable analysis

Type of urinary diversion (continent vs conduit)

0.63 (0.21-1.90)

0.41

Location of diversion (intra vs extracorporeal)

2.50 (0.95-6.80)

0.03

0.58 (0.26-1.30)

0.19

Intraoperative variables - multivariable analysis
Operating room time (≤6vs>6 h)
EBL (≤800 vs >800 mL)

3.26 (0.93-11.40)

0.06

Type of urinary diversion (continent vs conduit)

2.69 (0.93-7.77)

0.06

Hospital stay (<10 vs ≥10 days)

2.14 (1.00-4.56)

0.047

ICU stay

1.15 (0.94-1.42)

0.18

90-day readmission

32.35 (4.17-250.87)

0.0009

Hospital stay (<10 vs ≥10 days)

1.49 (0.60-3.80)

0.40

ICU stay

1.13 (0.92-1.40)

0.24

Postoperative variables - univariable analysis
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Postoperative variables - multivariable analysis
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Table 3
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Univariable and multivariate logistic regression analysis to evaluate variables associated with 90-day
mortality.
Variable

90-Day mortality
OR (95% CI)

P

Preoperative variables - univariable analysis
Gender (female vs male)

0.98 (0.41-2.34)

0.96

Age at surgery (10-year interval)

1.04 (0.70-1.55)

0.85

BMI (kg/m2)

1.10 (1.02-1.20)

0.013

Obese (BMI >30 kg/m2, yes/no)

3.40 (0.80-14.43)

0.096

Preoperative chemotherapy (yes/no)

3.35 (1.14-9.84)

0.028

Current smoker (yes/no)

3.29 (1.23-8.80)

0.018

ASA 3-4 vs1-2

1.69 (0.76-3.78)

0.20

Prior abdominal surgery

2.38 (1.10-5.13)

0.027

1.20 (0.42-3.46)

0.76

Preoperative variables - multivariable analysis
Gender (male vs female)

NIH-PA Author Manuscript

Age at surgery (10-year interval)
BMI

(kg/m2)

Current smoker (yes/no)

1.09 (0.65-1.82)

0.75

1.07 (0.99-1.16)

0.11

2.69 (0.90-8.10)

0.08

ASA (1-2 vs 3-4)

1.16(0.44-3.10)

0.77

Preoperative chemotherapy (yes/no)

2.32 (0.69-7.71)

0.17

Operating room time (≤6vs >6 h)

0.70 (0.32-1.54)

0.38

EBL (≤800 vs >800 mL)

1.82 (0.61-5.45)

0.29

Type of urinary diversion (continent vs conduit)

0.20 (0.04-0.93)

0.04

Location of diversion (intra vs extracorporeal)

1.30 (0.53-3.423)

0.54

Intraoperative variables - univariable analysis

Intraoperative variables - multivariable analysis
Operating room time (≤6vs >6 h)

0.63 (0.28-1.43)

0.27

EBL (≤800 vs >800 mL)

2.19 (0.70-6.77)

0.17

Type of urinary diversion (continent vs conduit)

1.38 (0.52-3.68)

0.52

Postoperative variables - univariable analysis

NIH-PA Author Manuscript

Hospital stay (<10 vs ≥10 days)

2.60 (1.20-5.60)

0.015

ICU stay

1.10 (0.95-1.27)

0.19

90-day readmission

3.39 (1.29-8.92)

0.013

Clavien 0 vs 3-5

0.15 (0.049-0.45)

0.0007

Clavien 1-2 vs Clavien 3-5

0.67 (0.24-1.87)

0.45

Hospital stay (<10 vs ≥10 days)

1.22 (0.47-3.14)

0.66

ICU stay

1.10 (0.92-1.25)

0.40

0.11 (0.01-1.47)

0.10

Complications

Postoperative variables - multivariable analysis

Complications
Clavien 0 vs 3-5
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90-Day mortality
OR (95% CI)

P

0.74 (0.23-2.33)

0.25
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